IP Library › Granted Patent US 8,653,275
Granted Patent B2
US 8,653,275 · App. 12/300,197 · Granted Feb 18, 2014

Patent

Inventors: Peter Crooks (Nicholasville, KY); Linda P. Dwoskin (Lexington, KY); Guangrong Zheng (Lexington, KY); Sangeetha Sumithran (Lexington, KY); Davis D. Allen (Rootstown, OH); Zhenfa Zheng (Lexington, KY); Paul Lockman (Amarillo, TX)
Assignee: University of Kentucky Research Foundation
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,653,275
App. No.
12/300,197
Granted
Feb 18, 2014
Kind
B2
Abstract

Provided are bis-quaternary ammonium cyclophane compounds which are modulators of nicotinic acetylcholine receptors. Also provided are methods of using the compounds for modulating the function of a nicotinic acetylcholine receptor, and for the prevention and/or treatment of central nervous system disorders, substance use and/or abuse, and or gastrointestinal tract disorders.

Claims (24)

1. A compound of Formula (I)

wherein

X 1Θ and X 2Θ are each independently an organic or inorganic anion;

Q and T are each independently attached to R 1 and R 2 ;

Q is alkyl;

T is alkynyl;

R 1 and R 2 are each six membered rings as shown in formula (IIA);

R 8 or R 12 is replaced by one attachment to T in R 1 and R 2 ;

R 4 is replaced by one attachment to Q in R 1 and R 2 ;

R 6 , R 8 , R 10 , R 12 , and R 14 , when present, are each independently selected from the group consisting of hydrogen, lower alkyl, halo, cyano, nitro, trifluoromethyl, hydroxymethyl, hydroxyethyl and hydroxypropyl.

2. The compound of claim 1 , wherein Q is —(CH 2 ) 4 —, —(CH 2 ) 6 —, —(CH 2 ) 8 —, —(CH 2 ) 9 —, —(CH 2 ) 10 —, —(CH 2 ) 11 — or —(CH 2 ) 12 —; and T is —C≡C—(CH 2 ) 6 —C≡C—.

3. The compound of claim 2 , wherein

X 1Θ and X 2Θ are bromide or iodide.

4. The compound of claim 1 selected from the group consisting of:

N,N′-(1,6-hexanediyl)-3,3′-(1,9-decanediyn-1,10-diyl)-bis-pyridinium diiodide;

N,N′-(1,8-octananediyl)-3,3′-(1,9-decanediyn-1,10-diyl)-bis-pyridinium diiodide;

N,N′-(1,9-nonanediyl)-3,3′-(1,9-decanediyn-1,10-diyl)-bis-pyridinium dibromide;

N,N′-(1,10-decanediyl)-3,3′-(1,9-decanediyn-1,10-diyl)-bis-pyridinium diiodide; and

N,N′-(1,11′-undecanediyl)-3,3′-(1,9-decanediyn-1,10-diyl)-bis-pyridinium dibromide.

5. A composition comprising a pharmaceutically acceptable carrier and a compound of claim 1 .

6. A composition comprising a pharmaceutically acceptable carrier and a compound of claim 2 .

7. A composition comprising a pharmaceutically acceptable carrier and a compound of claim 3 .

8. A composition comprising a pharmaceutically acceptable carrier and a compound of claim 4 .

9. N,N′-(1,4-butanediyl)-3,3′-(1,12-dodecanediyl)-bis-pyridinium diiodide.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 18, 2010
From: CROOKS, PETER; DWOSKIN, LINDA; ZHENG, GUANGRONG; SUMITHRAN, SANGEETHA; ALLEN, DAVID; ZHANG, ZHENFA; LOCKMAN, PAUL
To: UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION
Reel/Frame 024400/0063 →
Continuity (2)
Provisional Application 60799881 · May 12, 2006
Related Publication 20100222377A1 · Sep 2, 2010